These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19967967)

  • 1. [Important to keep the principle of value-based pricing of drugs].
    Persson U; Levin LA; Pettersson B
    Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2862-4. PubMed ID: 19967967
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

  • 3. The price of success: cost-effectiveness of molecularly targeted agents.
    Sleijfer S; Verweij J
    Clin Pharmacol Ther; 2009 Feb; 85(2):136-8. PubMed ID: 19151639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of preventive drugs. Dare to tell?
    Trewby PN
    BMJ; 2011 May; 342():d3198. PubMed ID: 21610062
    [No Abstract]   [Full Text] [Related]  

  • 5. Market watch: pricing strategies for emerging markets.
    Lineberry N; Snyder E; Gunda S
    Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
    [No Abstract]   [Full Text] [Related]  

  • 6. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 7. Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water.
    Neyt M
    Pharmacoeconomics; 2018 Jan; 36(1):1-3. PubMed ID: 28975551
    [No Abstract]   [Full Text] [Related]  

  • 8. The true cost of pharmacological disease prevention.
    Järvinen TL; Sievänen H; Kannus P; Jokihaara J; Khan KM
    BMJ; 2011 Apr; 342():d2175. PubMed ID: 21505222
    [No Abstract]   [Full Text] [Related]  

  • 9. Reimbursement for drugs -- a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions.
    Semark B; Fredlund K; Astrand B; Brudin L
    Scand J Public Health; 2009 Aug; 37(6):647-53. PubMed ID: 19546143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of drug pricing in australia, England, and new zealand.
    Raftery J
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):26-8. PubMed ID: 19274037
    [No Abstract]   [Full Text] [Related]  

  • 11. Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
    Ghabri S
    Pharmacoeconomics; 2024 Aug; 42(8):823-827. PubMed ID: 38733557
    [No Abstract]   [Full Text] [Related]  

  • 12. Value-based medicine pricing: NICE work?
    Webb DJ
    Lancet; 2011 May; 377(9777):1552-3. PubMed ID: 21093902
    [No Abstract]   [Full Text] [Related]  

  • 13. Reference drug pricing.
    Schneeweiss S; Soumerai SB; Maclure M
    CMAJ; 2002 Jul; 167(2):126-7; author reply 127-8. PubMed ID: 12160115
    [No Abstract]   [Full Text] [Related]  

  • 14. The Office of Fair Trading report: a prescription for value-based drug pricing.
    Minhas R; Moon JC
    J R Soc Med; 2007 May; 100(5):216-8. PubMed ID: 17470928
    [No Abstract]   [Full Text] [Related]  

  • 15. Spiraling drug costs: a call for cost-effective prescribing.
    Good CB
    J Am Geriatr Soc; 2005 Aug; 53(8):1427-9. PubMed ID: 16078975
    [No Abstract]   [Full Text] [Related]  

  • 16. [The cost of innovative drugs].
    Reggio S
    Recenti Prog Med; 1999; 90(7-8):371-2. PubMed ID: 10429514
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 19. Grounding Value-Based Drug Pricing in Population Health.
    Kaltenboeck A; Calsyn M; Frederix GWJ; Lowenthal J; Mitchell D; Rector B; Sarpatwari A
    Clin Pharmacol Ther; 2020 Jun; 107(6):1290-1292. PubMed ID: 31953850
    [No Abstract]   [Full Text] [Related]  

  • 20. Value based pricing for NHS drugs: an opportunity not to be missed?
    Claxton K; Briggs A; Buxton MJ; Culyer AJ; McCabe C; Walker S; Sculpher MJ
    BMJ; 2008 Feb; 336(7638):251-4. PubMed ID: 18244997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.